Neuren’s Partner Rolls Out New DAYBUE Formula Nationwide After 80% User Approval

Neuren’s partner Acadia rolls out DAYBUE STIX across the United States

Neuren Pharmaceuticals (ASX: NEU) has announced that its commercialisation partner Acadia Pharmaceuticals has launched broad availability of DAYBUE STIX Rett syndrome treatment across the United States. The dye-free and preservative-free powder formulation of trofinetide is approved for adults and paediatric patients aged two years and older, expanding access following a limited launch in Q1 2026.

The U.S. Food and Drug Administration approved DAYBUE STIX in December 2025. Acadia initially introduced the formulation on a limited basis during the first quarter of this year before scaling to nationwide availability in April 2026. This commercial expansion milestone directly impacts Neuren’s royalty revenue stream, as broader patient access translates to increased prescription volumes and sustained sales growth for the licensed therapy.

DAYBUE STIX represents Neuren’s approved treatment in the rare neurological disorder space, where the company holds an exclusive worldwide licensing agreement with Acadia for trofinetide’s development and commercialisation. The broader rollout positions the therapy to capture a larger share of the addressable Rett syndrome patient population across the United States.

What is Rett syndrome and why do treatment options matter?

Rett syndrome is a rare genetic neurological disorder that predominantly affects females, causing severe impairments in cognitive function, motor skills, and communication abilities. The condition typically manifests in early childhood, with patients experiencing progressive loss of purposeful hand use, distinctive hand-wringing movements, breathing irregularities, and seizures. Families and caregivers face significant challenges managing daily care requirements and navigating limited therapeutic options.

Before DAYBUE’s approval, no specific pharmacological treatments existed for Rett syndrome, with clinical management focusing primarily on symptomatic relief and supportive care. This represents a classic orphan drug market dynamic, where limited competition and high unmet medical need create sustained commercial opportunities for approved therapies. Neuren’s focus on insulin-like growth factor 1 (IGF-1) pathways addresses the underlying neurological mechanisms of the disorder, offering a targeted therapeutic approach distinct from symptomatic management alone.

The approval and subsequent formulation expansion of trofinetide marks a significant shift in the treatment landscape for Rett syndrome patients and their care teams. Access to an FDA-approved therapy provides physicians with an evidence-based intervention option, while families gain a pathway to potentially improving quality of life outcomes for affected individuals.

The DAYBUE STIX formulation advantage

DAYBUE STIX delivers trofinetide as a powder formulation designed to address practical administration challenges faced by caregivers. The dye-free and preservative-free composition reflects a streamlined ingredient profile, whilst the individual packet format enables portability for families managing treatment regimens outside clinical settings.

Caregivers can mix the powder with a variety of water-based liquids, providing customisation options to suit individual patient preferences. The formulation supports flexibility in daily treatment administration, a critical consideration for paediatric populations where taste and acceptance influence treatment adherence.

Key formulation features:

• Dye-free and preservative-free powder composition
• Individual packets for on-the-go administration
• Compatible with juice, tea, lemonade, limeade, and liquid hydration products
• Customisable mixing options for patient preference

The portability angle addresses a common barrier in rare disease treatment, where patients require consistent dosing across multiple daily settings including home, school, and therapy appointments. By reducing administration complexity, DAYBUE STIX potentially supports improved treatment adherence, which directly correlates with sustained prescription demand and revenue stability.

Early user feedback signals strong reception

Initial caregiver feedback from the limited launch phase indicates positive reception for the new formulation. Acadia reported that more than 80% of early users expressed satisfaction with DAYBUE STIX during the Q1 2026 limited availability period, highlighting the formulation’s flexibility and portability benefits.

Whilst this feedback derives from a small group of caregivers during the limited launch, the satisfaction metric provides an early indicator of product-market fit. High satisfaction rates typically correlate with positive word-of-mouth referrals among patient advocacy groups and increased physician confidence in prescribing, both of which support prescription growth as availability expands to the broader market.

For Neuren, strong user satisfaction during the rollout phase suggests the formulation may drive sustained adoption within the Rett syndrome patient community, reinforcing the durability of its royalty revenue stream from DAYBUE sales.

Expert consensus positions trofinetide as standard of care

A recent publication in Annals of Child Neurology has positioned trofinetide oral solution within the standard of care framework for Rett syndrome management. The consensus recommendations emerged from a steering group comprising experts based at International Rett Syndrome Foundation (IRSF)-designated centres of excellence, using a modified Delphi methodology to reach alignment on real-world clinical use.

The expert panel reached consensus on several key clinical considerations: recognising trofinetide as part of standard care for individuals with Rett syndrome, advocating for early treatment initiation, supporting sustained use over time, and emphasising individualised decision-making to optimise outcomes for patients, families, and caregivers. These recommendations reflect a shift in clinical practice guidelines that embeds trofinetide within comprehensive Rett syndrome management protocols.

Arthur Beisang, M.D., Department of Pediatrics, Gillette Children’s Specialty Healthcare

“The availability of DAYBUE STIX gives us an additional, flexible way to administer trofinetide, which allows us more options to address unique patient and caregiver needs. This patient-centred approach aligns with recently published expert consensus recommendations, which advocate for the integration of trofinetide as part of the standard of care and comprehensive Rett syndrome management. This new option provides additional customisation, supporting individualised care for people with Rett syndrome.”

The publication reference is: Prange EO, Beisang A, Pehlivan D, et al. Expert Consensus on Real-World Use of Trofinetide for Rett Syndrome Using a Modified Delphi Method. Ann Child Neurol. 2026; 4:38-51.

Expert endorsement and standard-of-care positioning strengthen DAYBUE’s competitive positioning within the rare disease treatment landscape. As the consensus recommendations become embedded in clinical practice guidelines, trofinetide gains institutional support that typically translates to sustained prescription growth and reduced commercial risk from competitive entry or treatment discontinuation.

What this means for Neuren’s commercial outlook

Neuren has granted an exclusive worldwide licence to Acadia Pharmaceuticals for the development and commercialisation of trofinetide, structuring the company’s revenue model around royalty payments and milestone achievements tied to Acadia’s sales performance. The DAYBUE STIX rollout represents a near-term commercial catalyst that expands the therapy’s addressable market whilst generating sustained royalty income.

Beyond DAYBUE, Neuren is advancing its proprietary development pipeline centred on NNZ-2591, an orally administered IGF-1 analogue targeting multiple neurodevelopmental disorders. The candidate has completed Phase 2 trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome, with each programme securing orphan drug designation in both the United States and European Union, alongside Fast Track and Rare Pediatric Disease designations from the FDA.

Neuren is currently conducting the Phase 3 Koala trial, a randomised, double-blind, placebo-controlled study evaluating NNZ-2591’s safety and efficacy in children aged 3 to 12 years with Phelan-McDermid syndrome, with a 52-week open-label extension study running concurrently. The company is also developing NNZ-2591 for hypoxic ischaemic encephalopathy (HIE), a condition caused by brain injury before or shortly after birth.

DAYBUE generates near-term royalty revenue whilst NNZ-2591 represents Neuren’s proprietary pipeline optionality across multiple rare disease indications with regulatory support designations. The combination of commercial-stage revenue from trofinetide and clinical-stage development across a diversified rare disease portfolio positions Neuren within the orphan drug development sector, where regulatory incentives and limited competition underpin commercial durability for approved therapies.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving biotech announcements delivered straight to your inbox the moment they drop.